STOCKHOLM, Feb. 28, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Skinobs, a leading global platform connecting researchers with the tools they need for their cosmetic and medical research. Through this partnership, SciBase will now offer Nevisense for assessing skin barrier function within cosmetic testing on the Skinobs platform.

Through the Skinobs platform, researchers can easily find information on who is conducting what tests in the field of dermocosmetic, nutraceutical, and active ingredient testing. This collaboration will streamline the process for researchers looking to access the latest tools for their cosmetic and medical research. The cosmetic testing market segment represents a significant potential addressable customer base for SciBase and is expected to grow exponentially into 2030.

"SciBase is already involved in discussions with several large cosmetic companies who wish to use Nevisense in their research and development. In May this year, SciBase will present and exhibit at its first cosmetic research-focused international conference, the Cosmetotest cosmetics testing symposium in Lyon, France," said Pia Renaudin, CEO at SciBase. "We are excited to be partnering with Skinobs to bring our innovative skin barrier function assessment technique to researchers globally. Nevisense is commonly utilized in medical research for assessing skin barrier health, hydration, healing, and inflammation, and we believe this partnership will extend our reach to cosmetic researchers in need of our products."

Skinobs provides cosmetic researchers around the world with easy access to preclinical and clinical testing methods and laboratories for evaluating active ingredients and cosmetic products on the skin, hair, or nails. Their platform covers a wide range of tests including stability, ecotoxicity, biodegradability, microbiology, safety, container/content interactions, sun protection, tolerance, efficacy, sensory analysis, and consumer tests.

For more information about SciBase's skin barrier function assessment tools available on the Skinobs platform, visit skinobs.com.

For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):

Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se

About Skinobs:

Skinobs is a French platform connecting researchers with the tools they need for cosmetic and medical research. With a focus on preclinical and clinical testing methods, Skinobs provides researchers with easy access to testing laboratories around the world.

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases

The following files are available for download:


     
     https://mb.cision.com/Main/12371/3936872/2632864.pdf Skinobs PR
                                                              final

View original content:https://www.prnewswire.co.uk/news-releases/scibase-partners-with-skinobs-to-offer-nevisense-on-global-cosmetic-testing-platform-302073809.html

Tags

More Like This

SciBase reaches milestone with over 400,000 tests sold with Nevisense

SciBase launches next generation Nevisense

SciBase announces sale of Nevisense to NIH (US)

SciBase Launches Nevisense Pilot at Leading University in Southeast Florida

Nevisense detects skin barrier damage from skin models in research

SciBase reaches milestone with over 300,000 patients tested with Nevisense

SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami